nach oben

Tipp

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer

verfasst von: Dominik Riss, MD, Johannes Pammer, MD, Matthaeus C. Grasl, MD, MME, Alexandra Kaider, MSc, Sven Schneider, MD, Boban M. Erovic, MD, PD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten

Summary

Purpose

To investigate the role of desmocollin 3 expression in radiation sensitivity and survival in squamous cell carcinoma of the head and neck.

Methods

Tissue samples of 40 patients undergoing primary radiotherapy were stained for desmocollin 3, a transmembrane desmosomal protein. The protein expression was determined by immunohistochemistry. A retrospective chart review was performed to assess overall survival, radiation sensitivity, and disease-free interval.

Results

18 of 40 patients showed desmocollin 3 immunoreactivity. 78 % (14/18) showed radiation sensitivity in the desmocollin 3 positive group, whereas 59 % (13/22) underwent remission in the desmocollin 3 negative group (p = 0.2). The median overall and disease-free survival time was 21 and 26 months, respectively. Univariate and multivariable Cox regression models revealed no statistically significant hazard ratios.

Conclusion

In this cohort of squamous cell carcinoma of the head and neck, we found no evidence for a predictive potential of desmocollin 3.

Vorheriger Artikel Evaluation of liver perfusion in diabetic patients using 99mTc-sestamibi

Nächster Artikel Elite level rhythmic gymnasts have significantly more and stronger pain than peers of similar age: a prospective study

Hardman MJ, Liu K, Avilion AA, et al. Desmosomal cadherin misexpression alters beta-catenin stability and epidermal differentiation. Mol Cell Biol. 2005;25(3):969–78. doi:10.1128/MCB.25.3.969-978.2005. PubMedCentralPubMedCrossRef

Fang WK, Gu W, Li EM, et al. Reduced membranous and ectopic cytoplasmic expression of DSC2 in esophageal squamous cell carcinoma: an independent prognostic factor. Hum Pathol. 2010;41(10):1456–65. doi:10.1016/j.humpath.2010.04.003. PubMedCrossRef

Delva E, Tucker DK, Kowalczyk AP. The desmosome. Cold Spring Harb Perspect Biol. 2009;1(2):a002543. doi:10.1101/cshperspect.a002543. PubMedCentralPubMedCrossRef

Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res. 2005;7(5):R669–80. doi:10.1186/bcr1273. PubMedCentralPubMedCrossRef

Wang L, Liu T, Wang Y, et al. Altered expression of desmocollin 3, desmoglein 3, and beta-catenin in oral squamous cell carcinoma: correlation with lymph node metastasis and cell proliferation. Virchows Arch. 2007;451(5):959–66. doi:10.1007/s00428-007-0485-5. PubMedCrossRef

Hamidov Z, Altendorf-Hofmann A, Chen Y, Settmacher U, Petersen I, Knosel T. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol. 2011;64(11):990–4. doi:10.1136/jclinpath-2011-200099. PubMedCrossRef

Klus GT, Rokaeus N, Bittner ML, et al. Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int J Oncol. 2001;19(1):169–74. PubMed

Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. PubMedCrossRef

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6. PubMedCrossRef

10.

Erovic BM, Pelzmann M, Grasl M, et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res. 2005;11(24 Pt 1):8632–6. doi:11/24/8632. [pii] 10.1158/1078-0432.CCR-05–1170. PubMedCrossRef

11.

Langer CJ. Exploring biomarkers in head and neck cancer. Cancer. 2012;118(16):3882–92. doi:10.1002/cncr.26718. PubMedCrossRef

12.

van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009;124(11):2643–50. doi:10.1002/ijc.24254. PubMedCrossRef

13.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36. doi:10.3322/caac.20121.

14.

Tselepis C, Chidgey M, North A, Garrod D. Desmosomal adhesion inhibits invasive behavior. Proc Natl Acad Sci U S A. 1998;95(14):8064–9.

15.

Chen J, O’Shea C, Fitzpatrick JE, Koster MI, Koch PJ. Loss of desmocollin 3 in skin tumor development and progression. Mol Carcinog. 2012;51:535–45. doi:10.1002/mc.20818.

16.

Rezze GG, Fregnani JH, Duprat J, Landman G. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011;42(3):409–18. doi:S0046-8177(10)00313-8 [pii] 10.1016/j.humpath.2010.09.004. PubMedCrossRef

17.

Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003;30(10):621–30. PubMedCrossRef

18.

Boelens MC, van den Berg A, Vogelzang I, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol. 2007;60(6):608–14. doi:jcp.2005.031443 [pii] 10.1136/jcp.2005.031443. PubMedCentralPubMedCrossRef

Titel: No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer
verfasst von: Dominik Riss, MD
Johannes Pammer, MD
Matthaeus C. Grasl, MD, MME
Alexandra Kaider, MSc
Sven Schneider, MD
Boban M. Erovic, MD, PD
Publikationsdatum: 01.01.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-014-0618-1

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer

Summary

Purpose

Methods

Results

Conclusion

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2015

Intrauterine device may trigger typical attacks of familial Mediterranean fever: a case report

Injury pattern in correlation with the height of fatal falls

Self-reported frequency and impact of hypoglycaemic events in insulin-treated diabetic patients in Austria

Red cell distribution width: a novel prognostic factor of pulmonary embolism?

Trichobezoar causing recurrent gastric ulcer and perforation

Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution